Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) EBT Margin (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed EBT Margin for 7 consecutive years, with 3414.15% as the latest value for Q4 2025.

  • Quarterly EBT Margin fell 232118.0% to 3414.15% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 892.04% through Dec 2025, down 33569.0% year-over-year, with the annual reading at 892.02% for FY2025, 33567.0% down from the prior year.
  • EBT Margin for Q4 2025 was 3414.15% at Kymera Therapeutics, down from 3350.9% in the prior quarter.
  • The five-year high for EBT Margin was 40.44% in Q4 2023, with the low at 3414.15% in Q4 2025.
  • Average EBT Margin over 5 years is 782.07%, with a median of 369.53% recorded in 2022.
  • The sharpest move saw EBT Margin soared 29870bps in 2021, then tumbled -232118bps in 2025.
  • Over 5 years, EBT Margin stood at 222.88% in 2021, then dropped by -8bps to 239.72% in 2022, then surged by 83bps to 40.44% in 2023, then tumbled by -2603bps to 1092.97% in 2024, then crashed by -212bps to 3414.15% in 2025.
  • According to Business Quant data, EBT Margin over the past three periods came in at 3414.15%, 3350.9%, and 737.76% for Q4 2025, Q3 2025, and Q2 2025 respectively.